Related Experiment Video
Updated: Jul 2, 2026
09:05
In Vitro Differentiation of Human Mesenchymal Stem Cells into Functional Cardiomyocyte-like Cells
Published on: August 9, 2017
MSC immune tolerance in cellular cardiomyoplasty
1Division of Cardiothoracic Surgery, Faculty of Medicine, McGill University, Montreal, Canada. ray.chiu@mcgill.ca
Seminars in Thoracic and Cardiovascular Surgery
|August 19, 2008
Summary
Allogeneic mesenchymal stem cells (MSCs) show promise for cardiac repair, but in vivo immune tolerance requires further investigation. Confirming their safety could enable readily available cell therapies for heart conditions.
Area of Science:
- Regenerative Medicine
- Immunology
- Cardiology
Background:
- Mesenchymal stem cells (MSCs) are being explored for cellular cardiomyoplasty.
- In vitro studies suggest MSCs possess immune tolerance, but in vivo data remain debated.
Purpose of the Study:
- To evaluate the potential of allogeneic and xenogeneic mesenchymal stem cells (MSCs) for cellular cardiomyoplasty.
- To address the ongoing controversies regarding the in vivo immune tolerance of MSCs.
Main Methods:
- Review of experimental and early clinical observations on MSCs in cardiac repair.
- Analysis of in vitro and in vivo immune tolerance data for allogeneic and xenogeneic MSCs.
Main Results:
- Increasing evidence supports the utility of allogeneic and xenogeneic MSCs for cardiac applications.
- Persistent controversies exist regarding the in vivo immune tolerance of MSCs.
Conclusions:
- Confirmation of allogeneic MSC feasibility for cardiomyoplasty has significant clinical implications.
- Successful allogeneic cell therapy offers convenient "off-the-shelf" options and avoids autologous MSC limitations.
